Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

No abstract is available for this paper.

• Publication year

  2015

• Venue

  British Journal of Haematology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.13285PMID 25659186
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• University of Groningen Studies on megakaryopoiesis in patients with myelodysplasia and idiopathic thrombocytopenic

  2017cited by this paper
• A pilot phase I dose finding safety study of the thrombopoietin‐receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

  2014cited by this paper
• Romiplostim for management of chemotherapy-induced thrombocytopenia

  2014cited by this paper
• Milestones in understanding platelet production: a historical overview

  2014cited by this paper
• Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia

  2014cited by this paper
• A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

  2014cited by this paper
• Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes

  2014cited by this paper
• Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin

  2013cited by this paper
• A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

  2013cited by this paper
• Absence of bi‐directional cross‐resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms

  2013cited by this paper
• Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim

  2013cited by this paper
• Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

  2013cited by this paper
• No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.

  2013cited by this paper
• How we treat lower-risk myelodysplastic syndromes.

  2013cited by this paper
• Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

  2013cited by this paper
• Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

  2013influential reference
• A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

  2012cited by this paper
• Platelet associated IgG may be related with thrombocytopenia in patients with myelodysplastic syndromes.

  2012cited by this paper
• Eltrombopag and improved hematopoiesis in refractory aplastic anemia.

  2012cited by this paper
• Revised international prognostic scoring system for myelodysplastic syndromes.

  2012cited by this paper
• Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia

  2012cited by this paper
• Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care

  2012cited by this paper
• Efficacy of Romiplostim in the Treatment of Chemotherapy Induced Thrombocytopenia (CIT) in a Patient with Mantle Cell Lymphoma

  2011cited by this paper
• Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.

  2011cited by this paper
• Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.

  2011cited by this paper
• Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome

  2011cited by this paper
• Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes

  2011cited by this paper
• Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

  2010cited by this paper
• Platelet formation.

  2010cited by this paper
• Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database

  2010cited by this paper
• Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

  2010cited by this paper
• Romiplostim or standard of care in patients with immune thrombocytopenia.

  2010cited by this paper
• Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials

  2009cited by this paper
• Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.

  2009cited by this paper
• Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS).

  2009cited by this paper
• Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

  2009cited by this paper
• Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

  2009cited by this paper
• Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

  2009influential reference
• Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

  2008influential reference
• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  2008cited by this paper
• A prognostic score for patients with lower risk myelodysplastic syndrome

  2008cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

  2008cited by this paper
• International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

  2008cited by this paper
• The incidence and impact of thrombocytopenia in myelodysplastic syndromes

  2007influential reference
• New thrombopoietic growth factors.

  2007cited by this paper
• Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

  2007influential reference
• Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres

  2007cited by this paper
• Defective Platelet Aggregation in Myelodysplastic Syndromes

  2007cited by this paper
• A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome.

  2007cited by this paper
• Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

  2007cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006influential reference
• Platelet mass has prognostic value in patients with myelodysplastic syndromes

  2006cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia.

  2006cited by this paper
• Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

  2006cited by this paper
• Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.

  2005cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study

  2005cited by this paper
• European consensus on grading bone marrow fibrosis and assessment of cellularity.

  2005cited by this paper
• Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.

  2004cited by this paper
• Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

  2004cited by this paper
• AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

  2004cited by this paper
• Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment

  2004cited by this paper
• The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.

  2004cited by this paper
• A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

  2003cited by this paper
• Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies

  2003cited by this paper
• Evaluating the prognosis of patients with myelodysplastic syndromes

  2002cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Myelodysplastic syndromes.

  2002cited by this paper
• Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

  2002cited by this paper
• Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high‐risk myelodysplastic syndrome

  2001cited by this paper
• Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases

  2001cited by this paper
• Platelet function in the myelodysplastic syndromes.

  2000cited by this paper
• Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes.

  2000cited by this paper
• Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production

  2000cited by this paper
• Characterization of Native Human Thrombopoietin in the Blood of Normal Individuals and of Patients with Haematologic Disorders

  1999cited by this paper
• The physiological response of thrombopoietin (c‐Mpl ligand) to thrombocytopenia in the rat

  1999cited by this paper
• Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia.

  1999cited by this paper
• Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes

  1998cited by this paper
• Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.

  1998cited by this paper
• Prognostic factors and scoring systems in myelodysplastic syndromes.

  1998cited by this paper
• Thrombopoietin levels after chemotherapy and in naturally occurring human diseases

  1998cited by this paper
• Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene.

  1998cited by this paper
• Thrombopoietin.

  1998cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

  1997cited by this paper
• Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.

  1997cited by this paper
• Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?

  1997cited by this paper
• Phase II study of roquinimex in myelodysplastic syndrome.

  1997cited by this paper
• Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization.

  1997cited by this paper
• Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro.

  1996cited by this paper
• Myelodysplastic syndromes.

  1996cited by this paper
• Regulation of Serum Thrombopoietin Levels by Platelets and Megakaryocytes in Patients with Aplastic Anaemia and Idiopathic Thrombocytopenic Purpura

  1996cited by this paper
• Serum Thrombopoietin (c-MpI Ligand) Levels in Patients with Liver Cirrhosis

  1996cited by this paper
• The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells.

  1996cited by this paper
• The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets.

  1995cited by this paper
• The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.

  1995cited by this paper
• Prognostic value of c-mpl expression in myelodysplastic syndromes.

  1995cited by this paper

• Platelet transfusion in adults: an update.

  2022cites this paper
• Comparing IgG Binding to Megakaryocytes in Thrombocytopenic Patients

  2022influential citation
• New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome

  2022cites this paper
• Lenalidomide and Eltrombopag for Treatment of Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Clinical Trial.

  2022cites this paper
• Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients

  2021cites this paper
• Current Management and New Developments in the Treatment of Myelodysplastic Syndrome.

  2021cites this paper
• Prise en charge des syndromes myélodysplasiques au Maroc à propos d´une étude mono-centrique

  2020cites this paper
• Myelodysplastic Syndromes

  2020cites this paper
• [Management of myelodysplastic syndromes in 2019: An update].

  2019cites this paper
• Human‐induced pluripotent stem cell‐derived blood products: state of the art and future directions

  2019cites this paper
• Mechanisms and therapeutic prospects of thrombopoietin receptor agonists.

  2019cites this paper
• Dual diagnosis of De novo Myelodysplastic Syndrome and Multiple Myeloma: Youngest Case to be Reported and Literature Review

  2019cites this paper
• Myelodysplastic syndromes current treatment algorithm 2018

  2018cites this paper
• The mutational landscape and microenvironment in Myelodysplastic Syndromes with deletion of chromosome 5 q THESIS FOR DOCTORAL DEGREE ( Ph . D . )

  2018cites this paper
• Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.

  2017cites this paper
• Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings

  2017cites this paper
• Infectious and bleeding complications in patients with hematological malignancies : Studies on diagnosis and prevention

  2017cites this paper
• No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

  2017cites this paper
• Chapter 31 - Blood, Blood Components, Plasma, and Plasma Products

  2016cites this paper
• Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura

  2016cites this paper
• Intraoral ecchymosis in myelodysplastic syndrome with myelofibrosis: A case report

  2016cites this paper
• Myelodysplastic Syndromes: Diagnosis and Treatment.

  2015influential citation
• Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management

  2015cites this paper
• Blood, Blood Components, Plasma, and Plasma Products

  2015cites this paper
• Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism

  2015cites this paper
• Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism.

  2015cites this paper